Information Provided By:
Fly News Breaks for February 4, 2020
Feb 4, 2020 | 06:44 EDT
Cantor Fitzgerald analyst Eliana Merle assumed coverage of Amicus Therapeutics with an Overweight rating and price target of $20, up from $19. The analyst sees "long-term underappreciated potential" and views 2020 as a key year for execution. The company's base business is undervalued at current share levels, says Merle, who sees "significant" long-term optionality from an emerging gene therapy platform.
News For FOLD From the Last 2 Days
There are no results for your query FOLD